文献速递乳腺癌消化系统肿瘤

乳腺癌肝转移:手术切除联合全身治疗对比单纯全身治疗的欧洲病例匹配分析

Surgical resection versus systemic therapy for breast cancer liver metastases: Results of a European case matched comparison.
PubMed 文献 · Eur J Cancer · 2018-03-23

该病例匹配分析比较荷兰全国登记的仅限肝脏的乳腺癌肝转移患者(全身治疗组,N=523)与法国肝胆中心接受肝切除联合全身治疗的患者(切除组,N=139)。匹配后切除组中位总生存82个月,全身治疗组31个月(HR 0.28,95%CI 0.15-0.52;P<0.001)。结论认为对选定患者,肝切除联合全身治疗可改善总生存。

要点

  • 匹配后肝切除组中位OS 82个月,全身治疗组31个月(HR 0.28,P<0.001)。
  • 匹配后切除组3年和5年OS分别为81%和69%,全身治疗组为32%和24%。
  • 肝切除联合全身治疗应考虑用于选定的乳腺癌肝转移患者。

核心结论

  • 对乳腺癌肝转移患者,肝切除联合全身治疗较单纯全身治疗改善总生存。
  • 肝切除应考虑用于选定的病例。

研究设计与样本

  • 病例匹配分析:荷兰全国登记的仅限肝脏的乳腺癌肝转移患者(全身治疗组,N=523)与法国肝胆中心接受肝切除联合全身治疗的患者(切除组,N=139)比较。
  • 匹配基于年龄、诊断年代、至转移间隔、最大转移灶大小、单发或多发肿瘤、诊断后化疗、内分泌或靶向治疗。
  • 1983年至2013年间共筛选3894例患者纳入。

主要发现

  • 总体中位随访80个月(95%CI 70-90个月)。
  • 全人群中位、3年和5年总生存分别为19个月、29%和19%。
  • 切除组与全身治疗组中位生存分别为73个月与13个月(P<0.001)。
  • 全身治疗组3年和5年生存分别为18%和10%,切除组分别为75%和54%。
  • 匹配后切除组中位OS 82个月,3年和5年OS分别为81%和69%;全身治疗组中位OS 31个月,3年和5年OS分别为32%和24%(HR 0.28,95%CI 0.15-0.52;P<0.001)。

关键数值与推荐

  • 匹配后切除组中位OS 82个月(3年OS 81%,5年OS 69%)。
  • 匹配后全身治疗组中位OS 31个月(3年OS 32%,5年OS 24%)。
  • 匹配后HR 0.28(95%CI 0.15-0.52;P<0.001)。

临床怎么用

  • 对仅限肝脏的乳腺癌肝转移患者,在选定病例中可考虑肝切除联合全身治疗以改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Resection of breast cancer liver metastases (BCLM) combined with systemic treatment is increasingly accepted but not offered as therapeutic option. New evidence of the additional value of surgery in these patients is scarce while prognoses without surgery remains poor. PATIENTS AND METHODS: For this case matched analysis, all nationally registered patients with BCLM confined to the liver in the Netherlands (systemic group; N = 523) were selected and compared with patients who received systemic treatment and underwent hepatectomy (resection group; N = 139) at a hepatobiliary centre in France. Matching was based on age, decade when diagnosed, interval to metastases, maximum metastases size, single or multiple tumours, chemotherapy, hormonal or targeted therapy after diagnosis. Based on published guidelines, palliative systemic treatment strategies are similar in both European countries. RESULTS: Between 1983 and 2013, 3894 patients were screened for inclusion. Overall median follow-up was 80 months (95% CI 70-90 months). The median, 3- and 5-year overall survival of the whole population was 19 months, 29% and 19%, respectively. The resection and systemic group had median survival of 73 vs. 13 months (P < 0.001), respectively. Three and 5-year survival was 18% and 10% for the systemic group and 75% and 54% for the resection group, respectively. After matching, the resection group had a median overall survival of 82 months with a 3- and 5-year overall survival of 81% and 69%, respectively, compared with a median overall survival of 31 months in the systemic group with a 3- and 5-year overall survival of 32% and 24%, respectively (HR 0.28, 95% CI 0.15-0.52; P < 0.001). CONCLUSIONS: For patients with BCLM, liver resection combined with systemic treatment results in improved overall survival compared to systemic treatment alone. Liver resection should be considered in selected cases.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ruiz A, van Hillegersberg R, Siesling S, et al. Surgical resection versus systemic therapy for breast cancer liver metastases: Results of a European case matched comparison. Eur J Cancer. 2018. PMID: 29579478. doi:10.1016/j.ejca.2018.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。